60,027 results match your criteria Clear Cell Renal Cell Carcinoma

COVID-19-associated hepatic artery pseudoaneurysms.

Liver Int 2022 Jun 24. Epub 2022 Jun 24.

AP-HP, Hôpital Necker Enfants Malades, Service d'Imagerie Adulte, Paris, France.

Cases of coronary and pulmonary artery pseudoaneurysms secondary to COVID-19 have been reported in the literature and are supposed to be secondary to inflammatory and vasculitis processes linked to a viral multisystem inflammatory syndrome. Although the incidence of COVID-19-associated liver injury ranges from 14% to 53% in hospitalized patients [5], COVID-19-associated hepatic artery pseudoaneurysms have never been reported so far. We present the case of a patient whose follow-up CT after cryoablation of renal cell carcinoma revealed seven fusiform pseudoaneurysms of the two hepatic arteries secondary to COVID-19. Read More

View Article and Full-Text PDF

Upper gastrointestinal bleeding secondary to late gastric metastasis of renal cell carcinoma.

Rev Esp Enferm Dig 2022 Jun 24. Epub 2022 Jun 24.

Aparato Digestivo, Hospital Universitario San Agustín, España.

Clear cell renal cell carcinoma is the most common renal neoplasm in adults. It has a relatively slow growth pattern that delays diagnosis until the onset of local, paraneoplastic or metastasis-related manifestations, and an unpredictable behavior ranging from aggressive tumors with poor short-term prognosis to late recurrence cases where metastases are identified years after nephrectomy, the latter scenario being the subject of the case we herein report. Read More

View Article and Full-Text PDF

The Significant Role of Tumor Volume on the Surgical Approach Choice, Surgical Complexity, and Postoperative Complications in Renal Cell Carcinoma With Venous Tumor Thrombus From a Large Chinese Center Experience.

Front Oncol 2022 7;12:869891. Epub 2022 Jun 7.

Department of Urology, Peking University Third Hospital, Beijing, China.

Objective: To explore the role of tumor volume (TV) on surgical approach choice, surgical complexity, and postoperative complications in patients with renal cell carcinoma (RCC) and inferior vena cava tumor thrombus.

Method: From January 2014 to January 2020, we retrospectively analyzed the clinical data of 132 patients who underwent radical nephrectomy with inferior vena cava thrombectomy (RN-IVCT). Primary renal tumor volume (PRTV), renal vein tumor thrombus volume (RVTTV), inferior vena cava tumor thrombus volume (IVCTTV), and total tumor thrombus volume (TTTV) were measured with the help of an internationally recognized 3D volume measurement software. Read More

View Article and Full-Text PDF

A rare case of tuberous sclerosis complex-associated renal cell carcinoma.

SA J Radiol 2022 20;26(1):2406. Epub 2022 May 20.

Department of Medical Genetics, Division of Molecular Biology and Human Genetics, Tygerberg Hospital, Stellenbosch University, Cape Town, South Africa.

Renal cell carcinoma is rarely described in paediatric patients with tuberous sclerosis complex. This report describes a case of an 11-year-old male with tuberous sclerosis-associated renal cell carcinoma. Read More

View Article and Full-Text PDF

Imaging of Clear Cell Renal Carcinoma with Immune Checkpoint Targeting Aptamer-Based Probe.

Pharmaceuticals (Basel) 2022 Jun 1;15(6). Epub 2022 Jun 1.

Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7a, 30-387 Krakow, Poland.

Immune checkpoint targeting immunotherapy has revolutionized the treatment of certain cancers in the recent years. Determination of the status of immune checkpoint expression in particular cancers may assist decision making. Here, we describe the development of a single-stranded aptamer-based molecular probe specifically recognizing human PD-L1. Read More

View Article and Full-Text PDF

CD21 B Cells Could Be a Potential Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma.

J Pers Med 2022 May 28;12(6). Epub 2022 May 28.

Department of Urology, Ehime University Graduate School of Medicine, Toon 791-0295, Japan.

Immune checkpoint inhibitor (ICI) therapy increases the risk of immune-related adverse events (irAEs). In particular, combination checkpoint blockade (CCB) targeting inhibitory CTLA-4 and PD-1 receptors could lead to irAEs at a higher rate than ICI monotherapy. Management of irAEs is important while using ICIs. Read More

View Article and Full-Text PDF

Association of Hypertension and Organ-Specific Cancer: A Meta-Analysis.

Healthcare (Basel) 2022 Jun 9;10(6). Epub 2022 Jun 9.

Department of Biomedical Engineering, University of Wisconsin, Milwaukee, WI 53211, USA.

Hypertension and cancer are two of the leading global causes of death. Hypertension, known as chronic high blood pressure, affects approximately 45% of the American population and is a growing condition in other parts of the world, particularly in Asia and Europe. On the other hand, cancer resulted in approximately 10 million deaths in 2020 worldwide. Read More

View Article and Full-Text PDF

Applied Change Management in Interventional Radiology-Implementation of Percutaneous Thermal Ablation as an Additional Therapeutic Method for Small Renal Masses.

Diagnostics (Basel) 2022 May 24;12(6). Epub 2022 May 24.

Institute for Management and Economics in Health Care, UMIT-University for Health Sciences, Medical Informatics and Technology, Eduard-Wallnoefer-Zentrum 1, A-6060 Hall in Tirol, Austria.

Interventional radiology (IR) has the potential to offer minimally invasive therapy. With this potential, new and arising IR methods may sometimes be in competition with established therapies. To introduce new methods, transformational processes are necessary. Read More

View Article and Full-Text PDF

Clinical Benefits of Indocyanine Green Fluorescence in Robot-Assisted Partial Nephrectomy.

Cancers (Basel) 2022 Jun 20;14(12). Epub 2022 Jun 20.

Division of Urology, Department of Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.

Background: To compare the intraoperative and postoperative outcomes of indocyanine green (ICG) administration in robot-assisted partial nephrectomy (RAPN) and report the differences in the results between patients with benign and malignant renal tumors.

Methods: From 2017 to 2020, 132 patients underwent RAPN at our institution, including 21 patients with ICG administration. Clinical data obtained from our institution's RAPN database were retrospectively reviewed. Read More

View Article and Full-Text PDF

Metastases to the Thyroid Gland: What Can We Do?

Cancers (Basel) 2022 Jun 19;14(12). Epub 2022 Jun 19.

Department of Thyroid Surgery, The First Hospital of China Medical University, 155 Nanjing Bei Street, Shenyang 110001, China.

Metastases to the thyroid gland arise from other malignant tumors such as renal cell carcinoma, colorectal cancer, lung cancer, and breast cancer. In clinical practice, the incidence is low, and the symptoms are not specific, so it is often missed and misdiagnosed. It is finally diagnosed via the comprehensive application of many diagnostic methods, such as ultrasound, fine-needle aspiration biopsy, and immunohistochemistry analysis. Read More

View Article and Full-Text PDF

PET-CT in Clinical Adult Oncology-IV. Gynecologic and Genitourinary Malignancies.

Cancers (Basel) 2022 Jun 18;14(12). Epub 2022 Jun 18.

Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT 84132, USA.

Concurrently acquired positron emission tomography and computed tomography (PET-CT) is an advanced imaging modality with diverse oncologic applications, including staging, therapeutic assessment, restaging and longitudinal surveillance. This series of six review articles focuses on providing practical information to providers and imaging professionals regarding the best use and interpretative strategies of PET-CT for oncologic indications in adult patients. In this fourth article of the series, the more common gynecological and adult genitourinary malignancies encountered in clinical practice are addressed, with an emphasis on Food and Drug Administration (FDA)-approved and clinically available radiopharmaceuticals. Read More

View Article and Full-Text PDF

Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab.

Cancers (Basel) 2022 Jun 16;14(12). Epub 2022 Jun 16.

Department of Urology, University Hospital Tuebingen, 72076 Tuebingen, Germany.

Background: The aim of this study was to evaluate the predictive and prognostic value of the systemic immune-inflammation index (SII) in patients with metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab plus nivolumab.

Methods: This retrospective study included forty-nine mRCC patients treated with first-line ipilimumab plus nivolumab at the Department of Urology of the University of Tuebingen, Germany. SII was assessed before starting ipilimumab plus nivolumab therapy at the time of first imaging and at tumor progression. Read More

View Article and Full-Text PDF

Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials.

Cancers (Basel) 2022 Jun 10;14(12). Epub 2022 Jun 10.

Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.

Immune checkpoint inhibitors (ICI) are now the bedrock for the treatment of metastatic renal cell carcinoma (RCC). Clear cell RCC (ccRCC) represents the most common subtype of this malignancy. Herein, we explore the therapeutic landscape of ccRCC by discussing the standard of care whose backbone consists of immune checkpoint inhibitors (ICI) and vascular endothelial growth factor inhibitors (VEGF). Read More

View Article and Full-Text PDF

Genome-Wide Meta-Analysis Identifies Variants in and That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib.

Cancers (Basel) 2022 Jun 8;14(12). Epub 2022 Jun 8.

Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

Individual response to sunitinib in metastatic renal cell carcinoma (mRCC) patients is highly variable. Earlier, sunitinib outcome was related to single nucleotide polymorphisms (SNPs) in and . Our aim is to provide novel insights into biological mechanisms underlying sunitinib action. Read More

View Article and Full-Text PDF

p53 and Its Isoforms in Renal Cell Carcinoma-Do They Matter?

Biomedicines 2022 Jun 6;10(6). Epub 2022 Jun 6.

Institute of Bioorganic Chemistry, Polish Academy of Sciences, 61-704 Poznan, Poland.

p53 is a transcription al factor responsible for the maintenance of cellular homeostasis. It has been shown that more than 50% of tumors are connected with mutations in the gene. These mutations cause a disturbance in cellular response to stress, and eventually, cancer development. Read More

View Article and Full-Text PDF

Micro-RNAs Predict Response to Systemic Treatments in Metastatic Renal Cell Carcinoma Patients: Results from a Systematic Review of the Literature.

Biomedicines 2022 May 31;10(6). Epub 2022 May 31.

Department of Medical Oral and Biotechnological Science, "G. d'Annunzio" University of Chieti and Pescara, 66100 Chieti, Italy.

Locally advanced or metastatic renal cell carcinomas (mRCCs) account for up to 15% of all kidney cancer diagnoses. Systemic therapies (with or without surgery) represent gold standard treatments, mostly based on tyrosine kinase inhibitors in association with immunotherapy. We provide an overview of the current knowledge of miRNAs as predictors of treatment resistance. Read More

View Article and Full-Text PDF

A promising Prognostic risk model for advanced renal cell carcinoma (RCC) with immune-related genes.

BMC Cancer 2022 Jun 23;22(1):691. Epub 2022 Jun 23.

Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.

Background: Renal cell carcinoma (RCC) is a third most common tumor of the urinary system. Nowadays, Immunotherapy is a hot topic in the treatment of solid tumors, especially for those tumors with pre-activated immune state.

Methods: In this study, we downloaded genomic and clinical data of RCC samples from The Cancer Genome Atlas (TCGA) database. Read More

View Article and Full-Text PDF

Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience.

Clin Transl Oncol 2022 Jun 23. Epub 2022 Jun 23.

Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.

Purpose: To explore the benefit yielded by radiotherapy (RT), we report a series of metastatic renal cell carcinoma (RCC) patients treated with concomitant RT plus Nivolumab.

Methods/patients: Patients undergoing Nivolumab treatment plus concomitant RT (ablative or palliative) were included. RT was defined Ablative if >5 Gy/fraction were delivered. Read More

View Article and Full-Text PDF

A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA).

Br J Cancer 2022 Jun 23. Epub 2022 Jun 23.

NHS Greater Glasgow and Clyde, Glasgow, UK.

Background: Surgery for renal cell carcinoma (RCC) with venous tumour thrombus (VTT) extension into the renal vein (RV) and/or inferior vena cava (IVC) has high peri-surgical morbidity/mortality. NAXIVA assessed the response of VTT to axitinib, a potent tyrosine kinase inhibitor.

Methods: NAXIVA was a single-arm, multi-centre, Phase 2 study. Read More

View Article and Full-Text PDF

Cancer immunohistogram representing cancer-immunity cycle by immunohistochemistry predicts the efficacy of immune checkpoint inhibitors in urological cancer patients.

Sci Rep 2022 Jun 23;12(1):10617. Epub 2022 Jun 23.

Department of Urology, Dokkyo Medical University, 880 Kitakobayashi, Mibu, Shimotsuga, Tokyo, 321-0293, Japan.

We developed an immunohistogram representing an individual cancer-immunity cycle based on immunohistochemical analyses. We evaluated its ability to predict the efficacy of immune checkpoint inhibitors (ICI) in 11 patients with urothelial carcinoma and 7 patients with renal cell carcinoma who underwent surgery and received ICIs for disease recurrence. Immunohistochemical analyses for CD8, TIA-1, HLA class I, HLA-DR, and PD-L1 were performed and scored 0-3. Read More

View Article and Full-Text PDF

[Metastatic renal cell carcinoma: Management of toxicities of combinations].

Bull Cancer 2022 Jun 20. Epub 2022 Jun 20.

Université Paris Saclay, institut Gustave-Roussy, Villejuif, France.

New combinations of antiangiogenic tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICI) or dual ICI have been shown to be effective in phase III trials compared to sunitinib in the first-line treatment of metastatic renal cell cancer. While ICI doublet is already used in other indications, TKI/ICI combinations are more recent and the management of their adverse effects (AEs) are less well known, particularly with regard to the accountability of each therapeutic class. The objective of this article is to analyze the safety data from the main phase III studies to provide clinicians with practical advice for managing the AEs from these combinations. Read More

View Article and Full-Text PDF

Expression of Is Epigenetically Regulated by DNA Methylation and Correlates with Immune Infiltrates in Clear-Cell Renal Cell Carcinoma.

Curr Issues Mol Biol 2022 May 25;44(6):2472-2489. Epub 2022 May 25.

Laboratory of Cytogenomics and Environmental Mutagenesis, Environment Section (SAMAM), Evandro Chagas Institute (IEC), BR 316, KM 7, s/n, Levilândia, Ananindeua 67030-000, PA, Brazil.

Clear cell renal cell carcinoma (KIRC) is the most common and highly malignant pathological type of kidney cancer, characterized by a profound metabolism dysregulation. As part of aspartate biosynthesis, mitochondrial (glutamic-oxaloacetic transaminase 2) is essential for regulating cellular energy production and biosynthesis, linking multiple pathways. Nevertheless, the expression profile and prognostic significance of in KIRC remain unclear. Read More

View Article and Full-Text PDF

Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)-Exploring Its Possible Clinical Relevance in Cancer Patients.

Curr Oncol 2022 Jun 7;29(6):4138-4147. Epub 2022 Jun 7.

Department of Pediatric Oncology, Faculty of Medicine, University Hospital Brno and Masaryk University, Cernopolni 9, 613 00 Brno, Czech Republic.

Sunitinib is a broad-spectrum multitargeted tyrosine kinase inhibitor mainly used as second-line therapy for non-resectable gastrointestinal stromal or first-line treatment option of metastatic renal cell carcinoma (mRCC), and as an "off-label" option in pediatric oncology. It has been previously reported that sunitinib elevates the mean corpuscular volume of erythrocytes (MCV) in treated subjects. The aim of this study was to assess time-dependent changes of this effect and evaluate its possible clinical relevance. Read More

View Article and Full-Text PDF

Noncoding-RNA mediated high expression of zinc finger protein 268 suppresses clear cell renal cell carcinoma progression by promoting apoptosis and regulating immune cell infiltration.

Bioengineered 2022 Apr;13(4):10467-10481

Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, Zha Bei Qu, China.

Clear cell renal cell carcinoma (ccRCC) is one of the most common malignant kidney tumors with a poor prognosis. Accumulating evidence proves that zinc finger protein 268 (ZNF268) is associated with tumor progression, but the detailed regulatory functions of ZNF268 in ccRCC require further exploration. Thus, here we aim to characterize the role of ZNF268 in ccRCC. Read More

View Article and Full-Text PDF

Preoperative Prediction of Inferior Vena Cava Wall Invasion of Tumor Thrombus in Renal Cell Carcinoma: Radiomics Models Based on Magnetic Resonance Imaging.

Front Oncol 2022 6;12:863534. Epub 2022 Jun 6.

Department of Radiology, Peking University First Hospital, Peking University, Beijing, China.

Objective: To develop radiomics models to predict inferior vena cava (IVC) wall invasion by tumor thrombus (TT) in patients with renal cell carcinoma (RCC).

Methods: Preoperative MR images were retrospectively collected from 91 patients with RCC who underwent radical nephrectomy (RN) and thrombectomy. The images were randomly allocated into a training (n = 64) and validation (n = 27) cohort. Read More

View Article and Full-Text PDF

A Rare Case of Sarcomatoid Renal Cell Carcinoma in a Young Adult Patient.

Res Rep Urol 2022 16;14:241-245. Epub 2022 Jun 16.

Division of Urology, Department of Surgery, Haji Adam Malik General Hospital - Universitas Sumatera Utara, Medan, Indonesia.

Background: Sarcomatoid differentiation is a rare condition that could present in different subtypes of renal cell carcinomas (RCCs) and is associated with a significantly poor prognosis. Sarcomatoid renal cell carcinoma (SRCC) patients are typically aged between 54 and 63, with a male-to-female ratio ranging from 1.3:1 to 2:1. Read More

View Article and Full-Text PDF

Identification of Ligand-Receptor Pairs Associated With Tumour Characteristics in Clear Cell Renal Cell Carcinoma.

Front Immunol 2022 6;13:874056. Epub 2022 Jun 6.

Department of Nephrology, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.

The tumour microenvironment (TME) of clear cell renal cell carcinoma (ccRCC) comprises multiple cell types, which promote tumour progression and modulate drug resistance and immune cell infiltrations ligand-receptor (LR) interactions. However, the interactions, expression patterns, and clinical relevance of LR in the TME in ccRCC are insufficiently characterised. This study characterises the complex composition of the TME in ccRCC by analysing the single-cell sequencing (scRNA-seq) data of patients with ccRCC from the Gene expression omnibus database. Read More

View Article and Full-Text PDF

Rituximab in Refractory Myositis and Acute Neuropathy Secondary to Checkpoint Inhibitor Therapy.

Cureus 2022 May 19;14(5):e25129. Epub 2022 May 19.

Department of Neurology, University of Florida, Gainesville, USA.

Checkpoint inhibitor immunotherapies have been one of the latest advances through the last decade in the treatment of various cancers. As their use is increasing so is the knowledge of their complications which can affect various organ systems including the central and peripheral nervous systems. Management of these complications requires stopping the offending agent and in some cases treating with immunosuppressive agents like intravenous steroids. Read More

View Article and Full-Text PDF

Non-Wilms' renal tumors in children: experience with 139 cases treated at a single center.

BMC Urol 2022 Jun 22;22(1):89. Epub 2022 Jun 22.

Department of Urology, National Children's Medical Center, Beijing Children's Hospital of Capital Medical University, No. 56 Nanlishi St, Xicheng District, Beijing, 100045, China.

Background: Pediatric non-Wilms renal tumors (NWRTs), which comprise a small proportion of renal tumors, are a heterogeneous group of neoplasms with variable malignant potential, mortality, and response to treatment. We performed this study to determine the clinical characteristics, management and prognosis of children with Pediatric NWRTs.

Methods: Medical records of all patients (n = 139) treated for NWRTs over a 12-year period (2008. Read More

View Article and Full-Text PDF

PET/MR Imaging of a Lung Metastasis Model of Clear Cell Renal Cell Carcinoma with (2S,4R)-4-[F]Fluoroglutamine.

Mol Imaging Biol 2022 Jun 22. Epub 2022 Jun 22.

Department of Urology, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

Purpose: Metabolic reprogramming plays an important role in the tumorigenesis of clear cell renal cell carcinoma (ccRCC). Currently, positron emission tomography (PET) reporters are not used clinically to visualize altered glutamine metabolism in ccRCC, which greatly hinders detection, staging, and real-time therapeutic assessment. We sought to determine if (2S,4R)-4-[F]fluoroglutamine ([F]FGln) could be used to interrogate altered glutamine metabolism in ccRCC lesions in the lung. Read More

View Article and Full-Text PDF